Enlivex stock soars to lead premarket gainers after getting OK to start Phase 2b trial of COVID-19 treatment
Shares of Enlivex Therapeutics Ltd.
soared 21.4% toward a five-month high, enough to pace all premarket gainers early Monday, after the Israel-based immunotherapy company said it received the OK to start a Phase 2b clinical trial for its treatment of severe and critical COVID-19 patients with acute respiratory distressed syndrome (ARDS). The Israel Ministry of Health authorized the trial after reviewing Phase 2 trial data. The Phase 2b trial is expected to recruit up to 152 patients in Israel and certain European countries, and is designed to evaluate the safety and efficacy of Allocetra when administered in addition to standard care treatment. The stock has rallied 20.6% year to date through Friday, while the S&P 500
has gained 19.0%.